Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia
- 14 December 2016
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 60 (3) , 531-540
Abstract
Aims/hypothesis Post-bariatric hypoglycaemia (PBH) is a rare, but severe, metabolic disorder arising months to years after bariatric surgery. It is characterised by symptomatic postprandial hypoglycaemia, with inappropriately elevated insulin concentrations. The relative contribution of exaggerated incretin hormone signalling to dysregulated insulin secretion and symptomatic hypoglycaemia is a subject of ongoing inquiry. This study was designed to test the hypothesis that PBH and associated symptoms are primarily mediated by glucagon-like peptide-1 (GLP-1). Methods We conducted a double-blinded crossover study wherein eight participants with confirmed PBH were assigned in random order to intravenous infusion of the GLP-1 receptor (GLP-1r) antagonist. Exendin (9-39) (Ex-9), or placebo during an OGTT on two separate days at the Stanford University Clinical and Translational Research Unit. Metabolic, symptomatic and pharmacokinetic variables were evaluated. Results were compared with a cohort of BMI- and glucose-matched non-surgical controls (NSCs). Results Infusion of Ex-9 decreased the time to peak glucose and rate of glucose decline during OGTT, and raised the postprandial nadir by over 70%, normalising it relative to NSCs and preventing hypoglycaemia in all PBH participants. Insulin AUC and secretion rate decreased by 57% and 71% respectively, and peak postprandial insulin was normalised relative to NSCs. Autonomic and neuroglycopenic symptoms were significantly reduced during Ex-9 infusion. Conclusions/interpretation GLP-1r blockade prevented hypoglycaemia in 100% of individuals, normalised beta cell function and reversed neuroglycopenic symptoms, supporting the conclusion that GLP-1 plays a primary role in mediating hyperinsulinaemic hypoglycaemia in PBH. Competitive antagonism at the GLP-1r merits consideration as a therapeutic strategy. Trial registration: ClinicalTrials.gov NCT02550145Keywords
Funding Information
- KL2 Mentored Career Development Award (KL2 TR 001083, L30 TR001569-01, UL1 TR 001085)
This publication has 50 references indexed in Scilit:
- Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in HumansDiabetes, 2011
- Trends in Hospital Volume and Operative Mortality for High-Risk SurgeryNew England Journal of Medicine, 2011
- Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes, 2011
- Peroral endoscopic anastomotic reduction improves intractable dumping syndrome in Roux-en-Y gastric bypass patientsSurgery for Obesity and Related Diseases, 2010
- Successful Medical Management of Status Post-Roux-en-Y-Gastric-Bypass Hyperinsulinemic HypoglycemiaObesity Surgery, 2009
- Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric bandingSurgery for Obesity and Related Diseases, 2007
- Long-Term Mortality after Gastric Bypass SurgeryNew England Journal of Medicine, 2007
- Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in HumansDiabetes Care, 2003
- Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes MellitusAnnals of Surgery, 2003
- Symptoms of Acute Insulin-Induced Hypoglycemia in Humans With and Without IDDM: Factor-Analysis ApproachDiabetes Care, 1991